SynthesisBMJ open2022
Thrombophilia screening in women with recurrent first trimester miscarriage: is it time to stop testing? - a cohort study and systematic review of the literature.
Synthesis in BMJ open, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Recurrent pregnancy loss: systematic review and meta-analysis of overall prevalence and the distribution of major etiological categories.Frontiers in medicine · 2026Pooled it
- Reported Prevalence of Inherited Thrombophilia in Pregnancy: Impact of Cohort Selection on Screening Implications-A Systematic Review.Diagnostics (Basel, Switzerland) · 2026Review
- Pregnancy and Assisted Reproductive Outcomes in Women with Systemic Lupus Erythematosus, Sjögren Syndrome and Antiphospholipid Syndrome: An Umbrella Review.Journal of clinical medicine · 2026Review
- Review
- Prevalence and factors associated with high-risk thrombophilia: a single-center cross-sectional study of 3550 patients at a tertiary Thrombosis Centre in Switzerland.Research and practice in thrombosis and haemostasis · 2025Article
- Non-Criteria Obstetric Antiphospholipid Syndrome: Myth or Reality?Journal of clinical medicine · 2025Review
- Prevalence of antiphospholipid syndrome among women with recurrent pregnancy loss: a cohort study.Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia · 2025Article
- [Obstetric Antiphospholipid Syndrome: Insights on the Diagnosis, Treatment, and Hot Issues].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2024Review
- Association of inherited thrombophilia mutations and their combinations among palestinian women with unexplained recurrent miscarriage.Thrombosis journal · 2024Article
- A point of view on hereditary thrombophilia and low-molecular-weight heparin incorporating the management in pregnancy and involving thyroidology.Revista da Associacao Medica Brasileira (1992) · 2023Article
- A Retrospective Assessment of Thrombophilia in Pregnant Women with First and Second Trimester Pregnancy Loss.International journal of environmental research and public health · 2022Observational
- Reproductive outcomes following recurrent first-trimester miscarriage: a retrospective cohort study.Human reproduction open · 2022Article
- "Unraveling the Clot-Miscarriage Nexus: Mechanisms, Management, and Future Directions in Thrombosis-Related Recurrent Pregnancy Loss".Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThere are numerous studies reporting a disproportionally high prevalence of thrombophilia in women with a history of recurrent miscarriage (RM), which has led to overdiagnosis and treatment without an improvement in clinical outcomes. The objective of our study was to assess the prevalence of inherited and acquired thrombophilia in a large cohort of women with a history of early RM using internationally agreed diagnostic criteria and inclusion parameters and compare it to the meta-analysis results of existing literature.
methods
designRetrospective cohort study and systematic review of literature.
settingThis is a retrospective cohort study set-up in two dedicated tertiary centres for women with RM in Southwest London and Surrey. We reviewed all the available literature related to causes of RMs. We ascertained the prevalence of thrombophilia in the study population and compared it with historical and published prevalence in the general population.
participants1155 women between 2012 and 2017. All patients had three or more first trimester miscarriages and a full thrombophilia screen.
resultsThe overall prevalence of thrombophilia in our study population is 9.2% (106/1155) with 8.1% (94/1155) of cases positive for inherited thrombophilia, which is similar to the general population; Factor V Leiden (4.9%; 57/1155) and prothrombin gene mutation (2.9%; 34/1155) were the most common inherited thrombophilias, while only 1% (12/1155) tested positive for acquired thrombophilia. Persistent positive lupus anticoagulant (LA) was found in 0.5% (6/1155) and persistent positive anticardiolipin (ACL) antibodies with a value ≥40 U/mL was found in 0.5% (6/1155) of patients. Tests for LA/ACL were performed a minimum of 12 weeks apart thus meeting the revised Sapporo criteria for a diagnosis of antiphospholipid syndrome.
conclusionThe findings of our study demonstrate that the prevalence of inherited thrombophilia is similar in women with RM to that in the general population. Similarly, the prevalence of acquired thrombophilia, using the revised Sapporo criteria, in the cohort of RMs is similar to that in the general population. Therefore, we do not recommend investigation or treatment of inherited or acquired thrombophilia in women with RM. PROSPERO REGISTRATION NUMBER: CRD42020223554.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.